Reference health
An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis
39/39 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
3 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 39 checked references that resolve
resolves10.1634/theoncologist.2008-0230
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
resolves10.1126/science.3798106
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene
resolves10.7150/jca.4090
HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature
resolves10.1016/S0140-6736(10)61121-X
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
resolves10.1016/S1470-2045(13)70102-5
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
resolves10.1200/jco.2013.31.15_suppl.4021
Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study.
resolves10.1093/annonc/mds211
Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis
resolves10.1186/1745-6215-8-16
Practical methods for incorporating summary time-to-event data into meta-analysis
resolves10.1186/1471-2288-11-41
Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Qstatistics
resolves10.1007/s00268-009-0142-z
Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer
resolves10.1002/jso.2930490402
Clinicopathological significance of c‐erbB‐2 protein expression in human gastric carcinoma
resolves10.1093/annonc/mdi064
Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab
resolves10.1093/annonc/mds506
A clinical–biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status
resolves10.3748/wjg.v17.i11.1501
Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma
resolves10.1200/jco.2013.31.15_suppl.4075
Prognostic impact of human epidermal growth factor-2 (HER2) status on overall survival (OS) of advanced gastric cancer (AGC) patients (pts) treated with standard chemotherapy without trastuzumab as a first-line treatment: A Japanese multicenter collaborative retrospective study.
resolves10.1093/jjco/hyg039
Prognostic Significance of p53, nm23, PCNA and c-erbB-2 in Gastric Cancer
resolves10.1093/annonc/mds104
Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis
resolves10.1002/jso.21781
ADAM 10 is associated with gastric cancer progression and prognosis of patients
resolves10.1038/sj.bjc.6604885
Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients
resolves10.1111/j.1349-7006.2012.02240.x
Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (<scp>HER</scp>2) and hormone receptor expression in uterine papillary serous carcinoma
resolves10.3346/jkms.1994.9.3.248
The prognostic significance of c-erbB-2 and p53 protein expressions in gastric carcinoma: a multivariate analysis of prognostic factors
resolves10.1159/000227559
Overexpression of c-ErbB-2 Protein in Gastric Cancer by Immunohistochemical Stain
resolves10.1007/BF03036740
The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma
resolves10.1177/106689690201000402
c-erb B-2 Expression Is Associated with Tumor Location and Venous Invasion and Influences Survival of Patients with Gastric Carcinoma
resolves10.4143/crt.2004.36.4.240
Prognostic Significance of Immunohistochemical Expression of EGFR and C-erbB-2 Oncoprotein in Curatively Resected Gastric Cancer
resolves10.3748/wjg.v19.i14.2171
Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer
resolves10.1002/jso.22022
Prognostic impact of microscopic positive margin in gastric cancer patients
resolves10.1093/annonc/mdn169
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
resolves10.1016/j.arcmed.2013.07.001
Prognostic Role of Human Epidermal Growth Factor Receptor in Gastric Cancer: A Systematic Review and Meta-analysis
resolves10.1111/j.1365-2559.2008.03028.x
Assessment of a HER2 scoring system for gastric cancer: results from a validation study
The 3 references without a DOI — listed, not checked
no DOI — not checkedYonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S, et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res. 1991;51:1034–8.
no DOI — not checkedKim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol. 2012;30:34–41.
no DOI — not checkedSeagroatt V, Stratton I. Bias in meta-analysis detected by a simple, graphical test. Test had 10% false positive rate. BMJ. 1998;316:470 (author reply -1).
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1007/s12094-017-1711-5"><img src="https://citestamp.com/citestamped/10.1007/s12094-017-1711-5/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1007/s12094-017-1711-5)